Real world evidence: Patients with refractory pemphigus treated with RituximabOriginal Research Paper Published on 2021-10-202024-09-04 Journal: Metabolism Open [Category] 대상포진, [키워드] autoimmune blistering disease biologic Efficacy Immunosuppression pemphigus rituximab Safety [DOI] 10.1016/j.metop.2021.100142 PMC 바로가기 [Article Type] Original Research Paper
Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysisarticle Published on 2021-10-132024-09-02 Journal: Frontiers in Neurology [Category] 대상포진, [키워드] Effectiveness Meta-analysis myasthenia gravis refractory rituximab [DOI] 10.3389/fneur.2021.736190 PMC 바로가기 [Article Type] article
A Young Patient with Microscopic Polyangiitis Requiring Hemodialysis with Complications of Repeated Episodes of Posterior Reversible Encephalopathy Syndrome Probably Due to Different EtiologiesCase Report Published on 2021-10-122024-09-04 Journal: Internal medicine (Tokyo, Japan) [Category] 대상포진, [키워드] Antineutrophil cytoplasmic antibody-associated vasculitis cerebral aneurysm dialysis Microscopic Polyangiitis Posterior reversible encephalopathy syndrome rituximab [DOI] 10.2169/internalmedicine.7941-21 PMC 바로가기 [Article Type] Case Report
Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient리툭시맙 치료 다발성 경화증 환자에서 COVID-19 백신 접종 후 급성 재발 및 불량한 면역Case Reports Published on 2021-10-032022-09-11 Journal: Human vaccines & immunotherapeutics [Category] MERS, SARS, 진단, 치료기술, [키워드] Adenovirus adenovirus-based adhere adverse event anti-CD20 anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody assessments Ataxia Autoimmune disease Autoimmune diseases Awareness cerebellar peduncle clinical trial clinician Corticosteroid corticosteroid therapy COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines decision Detection limit develop diagnosed dose Efficacy fatigue first dose FIVE Gam-COVID-Vac Immunity immunization lesions magnetic resonance imaging Mild symptom mild symptoms monoclonal antibody multiple sclerosis myalgia Neurological deficit neurological deficits oral steroid Patient Phase I raise receive receiving right hemiplegia risk rituximab SARS-CoV-2 steroid subpopulations the patient the vaccine treated Treatment vaccination schedule Vaccine Vaccines weakness [DOI] 10.1080/21645515.2021.1928463 PMC 바로가기 [Article Type] Case Reports
Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections선행 리툭시맙 유지 요법을 받은 여포성 림프종 환자에서 1년 지속되는 COVID-19 폐렴의 해결 및 면역 혈소판 감소증의 발병: 장기간 감염 사례에 대한 후속 보고서 및 문헌 검토Review Published on 2021-10-012022-09-11 Journal: Clinical lymphoma, myeloma & leukemia [Category] MERS, SARS, 진단, 치료기술, [키워드] anti-SARS-CoV-2 antibodies antibody approach Case report cellular immunity Chemotherapy convalescent plasma Convalescent plasma therapy coronavirus Course COVID-19 COVID-19 infection COVID-19 infections COVID-19 pneumonia development died disease course follicular Follicular lymphoma Follow-up Humoral immunity Immune thrombocytopenia Immunocompromised Itp. literature literature review lymphoma maintenance material Patient patients Pneumonia Prolonged prolonged disease receive report reported Resolution review risk rituximab subsequent T-cell Response the disease thrombocytopenia time-consuming [DOI] 10.1016/j.clml.2021.07.004 PMC 바로가기 [Article Type] Review
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression면역 억제를 받는 환자에서 SARS-CoV-2 백신 접종에 대한 체액 및 T 세포 반응Article Published on 2021-10-012022-09-11 Journal: Annals of the rheumatic diseases [Category] MERS, SARS, 진단, 치료기술, [키워드] antibody Antibody Response assays Autoimmune Autoimmune diseases B-cell B-lymphocytes BNT162b2 BNT162b2 mRNA ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccines Combination COVID-19 detectable Diseases Efficacy Evidence evidence of failure glomerular glomerular diseases healthy individuals immune responses immunogenic immunogenicity Immunological response Immunosuppression immunosuppressive immunosuppressive therapies immunosuppressive therapy impair induce investigated Lymphocytes mounted non-responder participant Patient preserved receiving responders response responses rituximab robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines Seroconversion seroconvert seroconverted serological serology T-cell ELISpot T-cell Response T-cell responses tacrolimus therapy vaccination Vaccine vaccine dose Vaccines were used [DOI] 10.1136/annrheumdis-2021-220626 PMC 바로가기 [Article Type] Article
Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed리툭시맙 치료 후 지속되는 중증 COVID-19 폐렴: 주의 필요Review Published on 2021-10-012022-09-12 Journal: Rheumatology International [Category] MERS, SARS, 진단, [키워드] Affect Atypical B cell biologic agent connective tissue Course COVID-19 COVID-19 in patient COVID-19 vaccine Cytokine storm disease Evidence humoral increased risk indicate indicated intense investigation life threatening outcome Patient performed Pneumonia recent rheumatic disease rituximab RTX SARS-CoV-2 SARS-COV-2 infection Severe COVID-19 pneumonia subject Systemic sclerosis Taking treated Treatment vaccination Vasculitis virus clearance [DOI] 10.1007/s00296-021-04969-2 PMC 바로가기 [Article Type] Review
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity리툭시맙 치료 환자에서 SARS-CoV-2 백신 접종: T 세포 매개 면역이 있는 경우 B 세포가 체액성 면역 반응을 촉진합니다Article Published on 2021-10-012022-09-11 Journal: Annals of the rheumatic diseases [Category] MERS, SARS, 진단, 치료기술, [키워드] Affect antibody assays B cell B cells BNT162b2 CD19 controls correlated COVID-19 detectable develop Elecsy enzyme enzyme-linked immunosorbent except for healthy control healthy individual healthy individuals humoral humoral immune response humoral immune responses IFN-γ immune response immune responses immunisation immunoassay independent independent of induce levels of antibody mounted mRNA mRNA-1273 n=36 neutralisation neutralisation tests Neutralising Antibodies neutralising antibody one patient Patient patients peripheral B cell peripheral B cells promote protective effect Protective effects quantified RBD Receptor-binding domain responses rituximab RTX SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 vaccination SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody SARS-CoV-2-specific T cell SARS-CoV-2-specific T cells SARS-CoV-2-specific T-cell response SARS-CoV-2-specific T-cell responses seroconverted significantly specific antibodies Spike protein T cells T-cell responses T-cell-mediated immunity the patient the receptor-binding domain the SARS-CoV-2 the spike protein therapy Treatment vaccination [DOI] 10.1136/annrheumdis-2021-220781 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study자가면역 염증성 류마티스 질환 성인 환자 및 일반 인구에서 BNT162b2 mRNA COVID-19 백신의 면역원성과 안전성: 다기관 연구Observational Study Published on 2021-10-012022-09-12 Journal: Annals of the rheumatic diseases [Category] MERS, SARS, 임상, 진단, [키워드] adverse event Autoimmune binding antibody unit biological therapy BNT162b2 mRNA BNT162b2 mRNA vaccine Control control group COVID-19 COVID-19 pandemic COVID-19 vaccine death defined Disease activity Efficacy evaluated Factor General population Glucocorticoids herpes zoster IgG IgG antibody IgG level immunogenic immunogenicity Inflammatory Major majority Messenger RNA methotrexate Mild MMF mRNA multicentre Older age Patient patients postvaccination Protein reduced remained rheumatic disease rituximab S1/S2 safety profile SARS-CoV-2 spike seronegative Seropositivity significantly significantly lower symptomatic case Treatment two-dose regimen vaccination Vaccine vaccine dose were assessed were measured [DOI] 10.1136/annrheumdis-2021-220647 PMC 바로가기 [Article Type] Observational Study
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab혈액 악성 종양이있는 Covid-19 환자에서 특정 항체의 생산 및 지속성 : 리툭시 맙의 역할Observational Study Published on 2021-09-142022-09-01 Journal: Blood Cancer Journal [Category] SARS, 임상, 진단, 치료기술, 치료법, [키워드] anti-S antibodies B-cell lymphoma CLD Clinical management Control controls COVID-19 COVID-19 patient declining develop diffuse large B-cell lymphoma DLBCL effective follicular Follicular lymphoma Haematological cancer hematologic Hematologic malignancy hematological HM patient HM patients humoral immune response immune response lymphoma lymphoproliferative disorder MONITOR Multiple myeloma nasal swab nasal swabs nine nucleocapsid Patient PCR-negative persistence Production Prospective Study Protein Reinfection rituximab SARS-CoV-2 SARS-CoV-2 nucleocapsid seroconversion rate seroconversion rates Seropositivity specific antibody syndrome the SARS-CoV-2 Treatment vaccination was performed were measured within 6 months [DOI] 10.1038/s41408-021-00546-9 PMC 바로가기 [Article Type] Observational Study